Septra for MRSA and Impetigo Treatment
Evidence for MRSA Coverage
- The Infectious Diseases Society of America (IDSA) recommends TMP-SMX as a first-line oral antibiotic option for empirical coverage of community-acquired MRSA in outpatients with skin and soft tissue infections, with an A-II level recommendation for purulent cellulitis 1, 2
- TMP-SMX provides reliable coverage against most community-acquired MRSA strains 3
Evidence for Impetigo Coverage
- Impetigo can be caused by both streptococci and S. aureus (including MRSA), and antibiotic selection must address both pathogens 4
- TMP-SMX provides excellent coverage for S. aureus including MRSA strains, but does not reliably cover β-hemolytic streptococci 1, 3
Critical Limitation: Streptococcal Coverage Gap
- When coverage for both β-hemolytic streptococci and CA-MRSA is desired, IDSA recommends either clindamycin alone, TMP-SMX or a tetracycline in combination with a β-lactam, or linezolid alone 1, 2
Clinical Decision Algorithm
- For impetigo with suspected MRSA involvement, TMP-SMX alone is appropriate if the infection appears purely purulent with no concern for streptococcal involvement, but add amoxicillin to TMP-SMX or switch to clindamycin monotherapy if classic impetigo features are present or streptococcal involvement cannot be excluded 1, 3
- For children with minor impetigo, topical mupirocin 2% ointment can be used as an alternative 2
Treatment Duration and Monitoring
- Treat for 5-10 days based on clinical response, and reevaluate within 24-48 hours to verify clinical response 1, 2
- Obtain cultures from purulent lesions if the patient has severe infection, systemic illness, or fails to respond to initial treatment 1